Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Ratos AB: Ratos Company TFS HealthScience acquires Appletree CI Group

Ratos

TFS HealthScience (TFS), a global contract research organization (CRO), acquires Appletree CI Group (Appletree) to enhance the company's existing expertise in the complex fields of ophthalmology, medical devices, and pediatric studies, simultaneously expanding geographic reach for clients.

Appletree CI Group was founded in 2013. The company is focused on five primary business areas; in addition to ophthalmology and medical devices, they have expertise in the fields of dermatology, pediatric trials, and regulatory affairs.

Ophthalmology is a rapidly growing field of medicine, with novel innovations and cutting-edge treatments for sight-threatening diseases.
"The acquisition is fully in line with Ratos strategy, where add-on acquisitions as part of growing existing companies in the group are an important part. We are proud of the successful development of TFS and look forward to a new year where TFS will play an important role in our increased commitment to professional services", says Anders Slettengren, Chairman of the board of TFS and Executive Vice President, Ratos.

The strategic acquisition of Appletree will complement TFS HealthScience's mission to be a market leader in ophthalmology research. The two companies will now offer complimentary and expanded service offerings to clients, including a specialized therapeutic focus in ophthalmology, significantly expanding the company's global footprint. 

"We are proud to partner with Appletree as we continue to provide our clients with in-depth, comprehensive knowledge and therapeutic expertise, particularly in the field of ophthalmology," said CEO of TFS HealthScience, Bassem Saleh. "This acquisition is a clear indicator of the growth and success of TFS. The partnership with Appletree will have a measurable impact on better treatments for patients and company growth, establishing a new presence in Switzerland and additional presence in Poland, Belgium, Hungary, and the U.K."

About TFS HealthScience

TFS HealthScience is a global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, they build solution-driven teams working for a healthier future. Bringing together nearly 800 professionals, TFS delivers tailored clinical research services in more than 40 countries.

About Appletree CI Group

Appletree CI Group is an expert niche CRO and global regulatory affairs service provider with track records in ophthalmology and medical device investigations. They are present in 11 European countries and have over 30 permanent staff. By having an in-depth understanding of local cultures and customs, as well as experience with national regulations they are able to facilitate your clinical development and regulatory projects.
For more information, please contact
Josefine Uppling, VP, Communication, Ratos, +46 76114 54 21, josefine.uppling@ratos.com
About Ratos
Ratos is a business group consisting of 16 companies divided into three business areas: Construction & Services, Consumer and Industry. The companies have approximately SEK 30 billion in net sales (LTM). Our business concept is to own and develop companies that are or can become market leaders. We have a distinct corporate culture and strategy - everything we do is based on our core values: Simplicity, Speed in execution and It's All About People. We enable independent companies to excel by being part of something larger. People, leadership, culture and values are key focus areas.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.